SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Bogestål Yalda Rahpeymai) "

Sökning: WFRF:(Bogestål Yalda Rahpeymai)

  • Resultat 1-5 av 5
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Henningsson, Louise, 1979, et al. (författare)
  • Interleukin 15 Mediates Joint Destruction in Staphylococcus Aureus Arthritis
  • 2012
  • Ingår i: Journal of Infectious Diseases. - : Oxford University Press (OUP). - 0022-1899 .- 1537-6613. ; 206:5, s. 687-696
  • Tidskriftsartikel (refereegranskat)abstract
    • Background. Staphylococcus aureus arthritis causes severe and rapid joint damage despite antibiotics. Thus, there is a need to identify new treatment targets in addition to antibiotics. Lately, interleukin 15 (IL-15) has been implicated both in osteoclastogenesis and in bacterial clearance-2 important issues in S. aureus-induced joint destruction. This has prompted us to investigate the importance of IL-15 in S. aureus-induced arthritis. Methods.Toxic shock syndrome toxin-1 producing S. aureus was intravenously inoculated in IL-15 knockout and wildtype mice and in wildtype mice treated with anti-IL-15 antibodies (aIL-15ab) or isotype control antibody. Results.Absence of IL-15, either in knockout mice or after treatment with aIL-15ab, significantly reduced weight loss compared with controls during the infection. The severity of synovitis and joint destruction was significantly decreased in IL-15 knockout and aIL-15ab treated mice compared with controls. In IL-15 knockout mice there was a reduced number of osteoclasts in the joints. The host's ability to clear bacteria was not influenced in the IL-15 knockout mice, but significantly increased after treatment with aIL-15ab. Conclusions.IL-15 is a mediator of joint destruction in S. aureus-induced arthritis and contributes to general morbidity, which makes this cytokine an interesting treatment target in addition to conventional antibiotics.
  •  
3.
  • Pekny, Milos, 1965, et al. (författare)
  • The role of astrocytes and complement system in neural plasticity.
  • 2007
  • Ingår i: International review of neurobiology. - 0074-7742. ; 82, s. 95-111
  • Forskningsöversikt (refereegranskat)abstract
    • In neurotrauma, brain ischemia or neurodegenerative diseases, astrocytes become reactive (which is known as reactive gliosis) and this is accompanied by an altered expression of many genes. Two cellular hallmarks of reactive gliosis are hypertrophy of astrocyte processes and the upregulation of the part of the cytoskeleton known as intermediate filaments, which are composed of nestin, vimentin, and GFAP. Our aim has been to better understand the function of reactive astrocytes in CNS diseases. Using mice deficient for astrocyte intermediate filaments (GFAP(-/-)Vim(-/-)), we were able to attenuate reactive gliosis and slow down the healing process after neurotrauma. We demonstrated the key role of reactive astrocytes in neurotrauma-at an early stage after neurotrauma, reactive astrocytes have a neuroprotective effect; at a later stage, they facilitate the formation of posttraumatic glial scars and inhibit CNS regeneration, specifically, they seem to compromise neural graft survival and integration, reduce the extent of synaptic regeneration, inhibit neurogenesis in the old age, and inhibit regeneration of severed CNS axons. We propose that reactive astrocytes are the future target for the therapeutic strategies promoting regeneration and plasticity in the brain and spinal cord in various disease conditions. Through its involvement in inflammation, opsonization, and cytolysis, complement protects against infectious agents. Although most of the complement proteins are synthesized in CNS, the role of the complement system in the normal or ischemic CNS remains unclear. Complement activiation in the CNS has been generally considered as contributing to tissue damage. However, growing body of evidence suggests that complement may be a physiological neuroprotective mechanism as well as it may participate in maintenance and repair of the adult brain.
  •  
4.
  • Rahpeymai Bogestål, Yalda, 1977, et al. (författare)
  • Signaling through C5aR is not involved in basal neurogenesis.
  • 2007
  • Ingår i: Journal of neuroscience research. - : Wiley. - 0360-4012 .- 1097-4547. ; 85:13, s. 2892-7
  • Tidskriftsartikel (refereegranskat)abstract
    • The complement system, an important part of the innate immune system, provides protection against invading pathogens, in part through its proinflammatory activities. Although most complement proteins are synthesized locally in the brain and the relevant complement receptors are expressed on resident brain cells, little is known about brain-specific role(s) of the complement system. C3a and C5a, complement-derived peptides with anaphylatoxic properties, have been implicated in noninflammatory functions, such as tissue regeneration and neuroprotection. Recently, we have shown that signaling through C3a receptor (C3aR) is involved in the regulation of neurogenesis. In the present study, we assessed basal neurogenesis in mice lacking C5a receptor (C5aR(-/-)) and mice expressing C3a and C5a, respectively in the CNS under the control of glial fibrillary acidic protein (GFAP) promoter (C3a/GFAP and C5a/GFAP, respectively) and thus without the requirement for complement activation. We did not observe any difference among C5aR(-/-), C3a/GFAP and C5a/GFAP mice and their respective controls in the number of newly formed neuroblasts and newly formed neurons in the subventricular zone (SVZ) of lateral ventricles and hippocampal dentate gyrus, the two neurogenic niches in the adult brain, or the olfactory bulb, the final destination of new neurons formed in the SVZ. Our results indicate that signaling through C5aR is not involved in basal neurogenesis in adult mice and that basal neurogenesis in adult C3a/GFAP and C5a/GFAP mice is not altered. (c) 2007 Wiley-Liss, Inc.
  •  
5.
  • Simonsson, Stina, 1969, et al. (författare)
  • Stem cell reprogramming: generation of patient-specific stem cells by somatic cell nuclear reprogramming.
  • 2009
  • Ingår i: Drug Discovery Today: Technologies. ; xxx:x
  • Forskningsöversikt (refereegranskat)abstract
    • Human embryonic stem cells (hESCs) are a very attractive supply in medicine, in particular as a human model system in drug discovery and developmental biology, but could also be used in cell replacement therapy. We are learning about molecular signaling pathways from several animal models, some of which are directly applicable to human beings. However, several pathways are unique for human cells and therefore culture of human tissue is an important tool to decipher molecular events in the human system. Human embryonic stem cells have several advantages including their capacity to multiply indefinitely in tissue culture and their ability to differentiate into any cell type of the body. Today, technology exists for producing embryonic stem cells (ESCs) containing patientspecific genome. These cells can multiply in tissue culture and upon external signals be induced to differentiate into any cell type of interest. In this way, patient-specific dopamine producing nerve cells can be transplanted to patients suffering from Parkinson’s disease or patient-specific skin cells can be grafted in individuals suffering from melanoma cancer. Such cells could also provide a unique model system for patientspecific drug screening. This review describes historical breakthroughs underlying these advances and some of the technical obstacles to overcome.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-5 av 5

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy